CRP and myocardial infarction: In a randomized, double-blind trial testing the effects of three doses of canakinumab on patients with a history of myocardial infarction and a high sensitivity C-reactive protein level, the results showed that canakinumab significantly reduced C-reactive protein levels and that anti-inflammatory therapy along with the 150 mg dose of canakinumab lowered the incidence of recurrent cardiovascular events compared to the placebo group with a hazard ratio of 0.85 [38].